^
Association details:
| Biomarker: | ALK fusion |
|---|---|
| Cancer: | Colorectal Adenocarcinoma |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target
Excerpt:
Colorectal carcinoma harboring ALK fusions represent a rare aggressive subtype of colorectal carcinoma with distinct clinicopathologic features. This report provides the first clinical evidence that such patients may benefit from targeted monotherapy with ALK inhibitors.
DOI:
10.1158/1078-0432.CCR-15-3000
